Literature DB >> 21931359

Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Rene Rodriguez1, Ruth Rubio, Pablo Menendez.   

Abstract

Because of their unique properties, multipotent mesenchymal stem cells (MSCs) represent one of the most promising adult stem cells being used worldwide in a wide array of clinical applications. Overall, compelling evidence supports the long-term safety of ex vivo expanded human MSCs, which do not seem to transform spontaneously. However, experimental data reveal a link between MSCs and cancer, and MSCs have been reported to inhibit or promote tumor growth depending on yet undefined conditions. Interestingly, solid evidence based on transgenic mice and genetic intervention of MSCs has placed these cells as the most likely cell of origin for certain sarcomas. This research area is being increasingly explored to develop accurate MSC-based models of sarcomagenesis, which will be undoubtedly valuable in providing a better understanding about the etiology and pathogenesis of mesenchymal cancer, eventually leading to the development of more specific therapies directed against the sarcoma-initiating cell. Unfortunately, still little is known about the mechanisms underlying MSC transformation and further studies are required to develop bona fide sarcoma models based on human MSCs. Here, we comprehensively review the existing MSC-based models of sarcoma and discuss the most common mechanisms leading to tumoral transformation of MSCs and sarcomagenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21931359      PMCID: PMC3351912          DOI: 10.1038/cr.2011.157

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  119 in total

1.  Bone marrow stromal cell-derived Wnt signals as a potential underlying mechanism for cyclin D1 deregulation in multiple myeloma lacking t(11;14)(q13;q32).

Authors:  Clara Bueno; Luiz F Lopes; Pablo Menendez
Journal:  Blood Cells Mol Dis       Date:  2007-07-13       Impact factor: 3.039

2.  Outgrowth of a transformed cell population derived from normal human BM mesenchymal stem cell culture.

Authors:  Y Wang; D L Huso; J Harrington; J Kellner; D K Jeong; J Turney; I K McNiece
Journal:  Cytotherapy       Date:  2005       Impact factor: 5.414

Review 3.  Concise review: mesenchymal tumors: when stem cells go mad.

Authors:  Alexander B Mohseny; Pancras C W Hogendoorn
Journal:  Stem Cells       Date:  2011-03       Impact factor: 6.277

4.  Aggressive fibromatosis (desmoid tumor) is derived from mesenchymal progenitor cells.

Authors:  Colleen Wu; Saeid Amini-Nik; Saied Nik-Amini; Puviindran Nadesan; William L Stanford; Benjamin A Alman
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

5.  Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2.

Authors:  Alexander B Mohseny; Karoly Szuhai; Salvatore Romeo; Emilie P Buddingh; Inge Briaire-de Bruijn; Daniëlle de Jong; Melissa van Pel; Anne-Marie Cleton-Jansen; Pancras C W Hogendoorn
Journal:  J Pathol       Date:  2009-11       Impact factor: 7.996

6.  Transformation of human mesenchymal stem cells in radiation carcinogenesis: long-term effect of ionizing radiation.

Authors:  Rikke Christensen; Jan Alsner; Flemming Brandt Sorensen; Frederik Dagnaes-Hansen; Steen Kolvraa; Nedime Serakinci
Journal:  Regen Med       Date:  2008-11       Impact factor: 3.806

7.  Expression of an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma.

Authors:  Padraic P Levings; Sean V McGarry; Thomas P Currie; David M Nickerson; Steven McClellan; Steven C Ghivizzani; Dennis A Steindler; C Parker Gibbs
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

8.  Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Manuel Masip; Purificación Catalina; Ana Nieto; Teresa de la Cueva; Mar Arriero; Nuria San Martin; Ernesto de la Cueva; Dimitrios Balomenos; Pablo Menendez; Javier García-Castro
Journal:  Neoplasia       Date:  2009-04       Impact factor: 5.715

9.  FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.

Authors:  Pedro A Pérez-Mancera; Camino Bermejo-Rodríguez; Manuel Sánchez-Martín; Fernando Abollo-Jiménez; Belén Pintado; Isidro Sánchez-García
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

10.  IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells.

Authors:  Luisa Cironi; Nicolò Riggi; Paolo Provero; Natalie Wolf; Mario-Luca Suvà; Domizio Suvà; Vincent Kindler; Ivan Stamenkovic
Journal:  PLoS One       Date:  2008-07-09       Impact factor: 3.240

View more
  60 in total

Review 1.  The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute.

Authors:  Jilong Yang; Zhiwu Ren; Xiaoling Du; Mengze Hao; Wenya Zhou
Journal:  Stem Cell Investig       Date:  2014-10-27

Review 2.  Bone microenvironment signals in osteosarcoma development.

Authors:  Arantzazu Alfranca; Lucia Martinez-Cruzado; Juan Tornin; Ander Abarrategi; Teresa Amaral; Enrique de Alava; Pablo Menendez; Javier Garcia-Castro; Rene Rodriguez
Journal:  Cell Mol Life Sci       Date:  2015-05-03       Impact factor: 9.261

3.  Mesenchymal Stem Cells: Miraculous Healers or Dormant Killers?

Authors:  Abbas Ghaderi; Shabnam Abtahi
Journal:  Stem Cell Rev Rep       Date:  2018-10       Impact factor: 5.739

Review 4.  Osteosarcoma: Molecular Pathogenesis and iPSC Modeling.

Authors:  Yu-Hsuan Lin; Brittany E Jewell; Julian Gingold; Linchao Lu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  Trends Mol Med       Date:  2017-07-20       Impact factor: 11.951

5.  Stem cell bioprocess engineering towards cGMP production and clinical applications.

Authors:  Sébastien Sart; Yves-Jacques Schneider; Yan Li; Spiros N Agathos
Journal:  Cytotechnology       Date:  2014-02-06       Impact factor: 2.058

Review 6.  Unraveling the journey of cancer stem cells from origin to metastasis.

Authors:  Rama Krishna Nimmakayala; Surinder K Batra; Moorthy P Ponnusamy
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-11-09       Impact factor: 10.680

Review 7.  Oncogenic Mutant p53 Gain of Function Nourishes the Vicious Cycle of Tumor Development and Cancer Stem-Cell Formation.

Authors:  Yoav Shetzer; Alina Molchadsky; Varda Rotter
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

8.  Widespread Chromatin Accessibility at Repetitive Elements Links Stem Cells with Human Cancer.

Authors:  Nicholas C Gomez; Austin J Hepperla; Raluca Dumitru; Jeremy M Simon; Fang Fang; Ian J Davis
Journal:  Cell Rep       Date:  2016-11-01       Impact factor: 9.423

9.  Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.

Authors:  Clara Bueno; Mar Roldan; Eduardo Anguita; Damia Romero-Moya; Beatriz Martín-Antonio; Michael Rosu-Myles; Consuelo del Cañizo; Francisco Campos; Regina García; Maite Gómez-Casares; Jose Luis Fuster; Manuel Jurado; Mario Delgado; Pablo Menendez
Journal:  Haematologica       Date:  2014-04-11       Impact factor: 9.941

10.  Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia.

Authors:  Spencer W Crowder; Linda W Horton; Sue Hyun Lee; Colt M McClain; Oriana E Hawkins; Amanda M Palmer; Hojae Bae; Ann Richmond; Hak-Joon Sung
Journal:  FASEB J       Date:  2013-04-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.